0000950170-24-057035.txt : 20240509 0000950170-24-057035.hdr.sgml : 20240509 20240509162221 ACCESSION NUMBER: 0000950170-24-057035 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240509 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: 4D Molecular Therapeutics, Inc. CENTRAL INDEX KEY: 0001650648 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 473506994 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39782 FILM NUMBER: 24931072 BUSINESS ADDRESS: STREET 1: 5858 HORTON STREET #455 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 5105052680 MAIL ADDRESS: STREET 1: 5858 HORTON STREET #455 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: 4D Molecular Therapeutics Inc. DATE OF NAME CHANGE: 20200506 FORMER COMPANY: FORMER CONFORMED NAME: 4D Molecular Therapeutics Inc DATE OF NAME CHANGE: 20150811 8-K 1 fdmt-20240509.htm 8-K 8-K
0001650648false00016506482024-05-092024-05-09

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 09, 2024

 

 

4D Molecular Therapeutics Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39782

47-3506994

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

5858 HORTON STREET

#455

 

EMERYVILLE, California

 

94608

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 510 505-2680

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

FDMT

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On May 9, 2024, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended March 31, 2024. A copy of 4DMT’s press release, titled “4DMT Reports First Quarter 2024 Financial Results and Operational Highlights” is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number

Description

99.1

Press Release, dated May 9, 2024, titled “4DMT Reports First Quarter 2024 Financial Results and Operational Highlights”

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

4D MOLECULAR THERAPEUTICS, INC.

 

 

 

 

Date:

May 9, 2024

By:

/s/ Uneek Mehra

 

 

 

Uneek Mehra
Chief Financial and Business Officer

 

 

 EX-99.1 2 fdmt-ex99_1.htm EX-99.1 EX-99.1

 

Exhibit 99.1

4DMT Reports First Quarter 2024 Financial Results and Operational Highlights

•
Announced positive interim data from PRISM Phase 2 Dose Expansion cohort evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden enabling advancement into Phase 3 expected by Q1 2025
•
Interim 24-week landmark analysis from PRISM Phase 2 Population Extension cohort evaluating 4D-150 in broader wet AMD population expected to be presented at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting on July 17-20, 2024
•
Interim clinical data from Phase 1/2 AEROW clinical trial expected to be presented at the European Cystic Fibrosis Society (ECFS) Conference on June 5-8, 2024
•
Announced positive interim data for 4D-310 in Fabry disease cardiomyopathy, demonstrating durable responses on cardiac endpoints and promising cardiac biopsy results
•
Completed upsized public follow-on offering with total gross proceeds of $337 million; $589 million in cash and equivalents as of March 31, 2024 expected to fund operations into H1 2027

 

EMERYVILLE, Calif., May. 9, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today reported first quarter 2024 financial results and provided operational highlights.

 

“The first quarter of 2024 kicks off another transformative year for 4DMT with exceptional progress across our product pipeline and platform in multiple therapeutic areas, particularly our lead program 4D-150 in large market VEGF-driven retinal diseases,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. “With robust clinical activity from 4D-150 demonstrated in our initial interim 24-week results from the Phase 2 PRISM Dose Expansion cohort in the severe disease activity wet AMD patient population, we set the stage for additional important data readouts in 2024, including 24-week results from the Phase 2 PRISM Population Extension cohort in the broader wet AMD patient population expected to be announced at ASRS in July and 24-week results from the Phase 2 SPECTRA Dose Confirmation cohort in DME expected to be announced in the fourth quarter. We believe the emerging profile of 4D-150 shows its potential to be the best-in-class, long-acting genetic medicine for broad market use in VEGF-driven retinal diseases, and we look forward to completing alignment with the FDA and EMA to rapidly advance 4D-150 into its first pivotal trial for global development. Building on the success of intravitreal R100, we are also encouraged by the preclinical results from 4D-175 that we shared today at the 2024 Association for Research in Vision and Ophthalmology (ARVO) Annual Scientific Meeting and are looking forward to bringing the program into the clinic for treatment of geographic atrophy in the second half of the year, demonstrating the power of our modular vectors and product engine. In addition, we continue to advance towards important milestones for 4D-710 for cystic fibrosis, 4D-725 for A1AT deficiency and 4D-310 for Fabry disease cardiomyopathy. Our successful financing puts us in a strong position to execute on all our corporate objectives, with expected cash runway into the first half of 2027.”

 

Recent Highlights in Large Market Ophthalmology Portfolio

•
4D-150 for Wet Age-Related Macular Degeneration (wet AMD):
o
Rapidly advanced intravitreal 4D-150 for wet AMD in the Phase 2 PRISM clinical trial
▪
Randomized Dose Expansion cohort (N=51) in patients with severe disease activity and high treatment burden presented at Angiogenesis, Exudation, and Degeneration 2024 Conference in February (data cutoff January 19, 2024):

 

 

•
Favorable safety profile demonstrated, with no significant or recurrent intraocular inflammation, and no 4D-150–related serious adverse events (SAEs) or study eye SAEs; All patients were off steroids
•
At 24 weeks, high dose of 4D-150 (3E10 vg/eye) resulted in robust reductions in overall treatment burden of 89%, percent of patients with 0-1 injections of 84%, percent of patients injection-free of 63%, plus improved retinal anatomical control vs. the aflibercept control arm
▪
Durable responses demonstrated beyond one year in Phase 1 3E10 vg/eye dose cohort, with three patients injection-free through 80–104 weeks (up to 2 years) of follow-up
o
Announced preliminary pivotal Phase 3 clinical trial design with additional regulatory interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) under RMAT (Regenerative Medicine Advanced Therapy) and PRIME (Priority Medicines) designations underway
o
Successfully completed the qualified person (QP) inspection of our GMP manufacturing facilities and operations resulting in issuance of a QP Declaration enabling distribution of investigational medicinal products (IMP) in the EU territories
•
4D-175 for Geographic Atrophy:
o
Preclinical data for 4D-175 for geographic atrophy presented in an oral presentation at the 2024 ARVO Annual Scientific Meeting in May:
▪
Short-form complement factor H (sCFH) transgene-derived protein showed functional activity consistent with wild type full-length CFH inin vitroexperiments
▪
Dose-dependent transgene expression and inhibition of alternative complement pathway by 4D-175 demonstrated in human retinal pigment epithelium (RPE) cells
▪
Intravitreal administration of 4D-175 to non-human primates (NHP) was safe and well tolerated and resulted in robust transgene expression in the retina and RPE/choroid, resulting in sCFH levels above target therapeutic concentrations in the aqueous humor
▪
Presentation can be found on our website under Scientific Presentations

 

Recent Highlights in Pulmonology Portfolio

•
4D-710 for Cystic Fibrosis (CF) Lung Disease:
o
Nine patients dosed to-date in Phase 1/2 AEROW clinical trial across four dose levels (range of 2.5E14 to 2E15 vg)
o
Conducted initial pivotal study interactions with the FDA and EMA; Company has clear registration path for 4D-710 for treatment of cystic fibrosis (CF) lung disease in people with CF who are ineligible for or cannot tolerate approved CF modulator therapies
o
Completed in-house process development of a suspension Good Manufacturing Practice (GMP) ready manufacturing process for 4D-710 at 500 liter scale for the pivotal study

 

Recent Highlights in Cardiology Portfolio

•
4D-310 for Fabry Disease Cardiomyopathy:
o
Interim clinical and biopsy data from Phase 1/2 INGLAXA clinical trials presented in the late-breaking session at WORLDSymposium™ 2024 in February:
▪
4D-310 demonstrated clinically meaningful improvements on multiple cardiac endpoints through 12-24 months in five evaluable patients

 

 

▪
Cardiac biopsies from one patient at week 6 and 24 showed robust and durable delivery, transgene expression and clearance of Gb3 substrate in cardiomyocytes
▪
Safety and tolerability profile maintained; previously reported cases of atypical hemolytic uremic syndrome (aHUS) (n=3) have fully resolved

 

Expected Upcoming Milestones

•
4D-150 for Wet AMD:
o
Phase 2 PRISM Population Extension cohort (N=32) in the broader wet AMD patient population:
▪
Initial interim 24-week landmark analysis expected to be presented at the ASRS Annual Scientific Meeting on July 17-20, 2024
o
Phase 3 planning:
▪
Update on Phase 3 clinical trial design expected in Q3 2024
▪
First Phase 3 clinical trial initiation expected in Q1 2025
•
4D-150 for DME:
o
Phase 2 SPECTRA clinical trial Dose Confirmation cohort (N=22):
▪
Initial interim 24-week landmark analysis expected in Q4 2024
•
4D-175 for Geographic Atrophy:
o
IND filing expected in Q2 2024
o
Phase 1 initiation expected in H2 2024
•
4D-710 for CF Lung Disease:
o
Phase 1/2 AEROW clinical trial interim clinical data expected at the ECFS Conference on June 5-8, 2024, including safety, lung biomarker and clinical activity data on all nine patients dosed across four dose level cohorts
▪
Phase 2 Expansion cohort dose selection expected to be shared in conjunction with interim data at ECFS
o
Phase 3 pivotal trial initiation expected in H2 2025
•
4D-725 for Alpha-1-Antitrypsin (A1AT) Deficiency Lung Disease:
o
Program update expected in 2024
•
4D-310 for Fabry Disease Cardiomyopathy:
o
FDA submission of preclinical NHP safety data in combination with rituximab/sirolimus immunosuppression regimen expected in Q2 2024
•
4D-110 for Choroideremia and 4D-125 for X-Linked Retinitis Pigmentosa:
o
Program updates expected in 2024

 

Q1 2024 Financial Results

 

Cash and Cash Equivalents and Marketable Securities: Cash and cash equivalents and marketable securities were $589 million as of March 31, 2024, as compared to $299 million as of December 31, 2023. The net increase in cash was primarily a result of cash inflows from approximately $316 million of net proceeds from our public offering of common stock completed in February including partial exercise of

 

 

underwriters’ option to purchase additional shares. We currently expect cash and cash equivalents to be sufficient to fund operations into the first half of 2027.

 

R&D Expenses:Research and development expenses were $27.9 million for the first quarter of 2024, as compared to $22.4 million for the first quarter of 2023. This increase was driven by the progression of our existing clinical trials, primarily 4D-150 in wet AMD and DME, along with increased payroll and stock-based compensation expense due to higher headcount.

 

G&A Expenses:General and administrative expenses were $10.3 million for the first quarter of 2024, as compared to $8.0 million for the first quarter of 2023.

 

Net Loss:Net loss was $32.4 million for the first quarter of 2024, as compared to net loss of $28.7 million for the first quarter of 2023.

 

About 4DMT

 

4DMT is a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT’s proprietary invention platform, Therapeutic Vector Evolution, combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our product design, development, and manufacturing engine helps us efficiently create and advance our diverse product pipeline with the goal of revolutionizing medicine with potential curative therapies for millions of patients. Currently, 4DMT is advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases in ophthalmology, pulmonology, and cardiology. In addition, 4DMT is also advancing programs in CNS through a gene editing partnership. 4D Molecular Therapeutics™, 4DMT®, 4D®, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

 

All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the FDA or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.

 

Learn more at www.4DMT.comand follow us on LinkedIn.

 

Forward Looking Statements:

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the therapeutic potential, and clinical benefits of, as well as the plans, announcements and related timing for the clinical development of, 4DMT’s product candidates, and statements regarding our financial performance, results of operations and anticipated cash runway. The words "may," “might,” "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," “expect,” "estimate," “seek,” "predict," “future,” "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including risks and uncertainties that are described in greater detail in the section entitled "Risk Factors" in 4D Molecular Therapeutics’ most recent Quarterly Report on Form 10-Q to be filed on or about the date hereof, as well as any subsequent filings

 

 

with the Securities and Exchange Commission. In addition, any forward-looking statements represent 4D Molecular Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. 4D Molecular Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

 

 

 

 

 

4D Molecular Therapeutics, Inc.

Statements of Operations

(Unaudited)

(in thousands, except share and per share amounts)

 

 

 

Three months ended March 31,

 

 

 

2024

 

 

2023

 

Revenue:

 

 

 

 

 

 

Collaboration and license revenue

 

$

28

 

 

$

298

 

Operating expenses:

 

 

 

 

 

 

Research and development

 

 

27,870

 

 

 

22,412

 

General and administrative

 

 

10,294

 

 

 

7,992

 

Total operating expenses

 

 

38,164

 

 

 

30,404

 

Loss from operations

 

 

(38,136

)

 

 

(30,106

)

Other income, net

 

 

5,735

 

 

 

1,424

 

Net loss

 

$

(32,401

)

 

$

(28,682

)

Net loss per share, basic and diluted

 

$

(0.66

)

 

$

(0.88

)

Weighted-average shares outstanding used in computing net loss per share, basic and diluted

 

 

49,271,984

 

 

 

32,723,530

 

 

 

 

 

 

4D Molecular Therapeutics, Inc.

Balance Sheet Data

(Unaudited)

(in thousands)

 

 

 

March 31,

 

 

December 31,

 

 

 

2024

 

 

2023

 

Cash, cash equivalents and marketable securities

 

$

588,853

 

 

$

299,186

 

Working capital

 

 

519,186

 

 

 

277,637

 

Total assets

 

 

629,884

 

 

 

339,891

 

Total liabilities

 

 

29,323

 

 

 

32,062

 

Accumulated deficit

 

 

(447,728

)

 

 

(415,327

)

Total stockholders’ equity

 

 

600,561

 

 

 

307,829

 

 

 

 

 

Contacts:

 

Media:

 

Katherine Smith

Inizio Evoke Comms

Katherine.Smith@inizioevoke.com

 

Investors:

 

Julian Pei

Head of Investor Relations and Corporate Communications

Investor.Relations@4DMT.com

 

 

img216297824_0.jpg 

 

 GRAPHIC 3 img216297824_0.jpg GRAPHIC begin 644 img216297824_0.jpg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end EX-101.SCH 4 fdmt-20240509.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document And Entity Information
May 09, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 09, 2024
Entity Registrant Name 4D Molecular Therapeutics Inc.
Entity Central Index Key 0001650648
Entity Emerging Growth Company true
Entity File Number 001-39782
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 47-3506994
Entity Address, Address Line One 5858 HORTON STREET
Entity Address, Address Line Two #455
Entity Address, City or Town EMERYVILLE
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94608
City Area Code 510
Local Phone Number 505-2680
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol FDMT
Security Exchange Name NASDAQ
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports fdmt-20240509.htm fdmt-20240509.xsd http://xbrl.sec.gov/dei/2023 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "fdmt-20240509.htm": { "nsprefix": "fdmt", "nsuri": "http://www.4dmoleculartherapeutics.com/20240509", "dts": { "inline": { "local": [ "fdmt-20240509.htm" ] }, "schema": { "local": [ "fdmt-20240509.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_cb1cd569-9c2a-4f79-b9b3-514b576d944e", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240509.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cb1cd569-9c2a-4f79-b9b3-514b576d944e", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240509.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0000950170-24-057035-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-057035-xbrl.zip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false 8-K 2024-05-09 4D Molecular Therapeutics Inc. DE 001-39782 47-3506994 5858 HORTON STREET #455 EMERYVILLE CA 94608 510 505-2680 false false false false Common Stock, $0.0001 par value per share FDMT NASDAQ true false